# US 2020/0139094 A1 · Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0139094 A1
- Document ID: US20200139094A1
- Status: Published application
- Kind: A1
- Application number: 16/268,189
- Filed: 2019-02-05
- Published: 2020-05-07
- Earliest claimed: 2010-12-23
- Assignees: Rani Therapeutics, LLC
- Applicants: Rani Therapeutics, LLC
- Inventors: Mir Imran
- Web page: https://patentgrep.com/patent/US20200139094A1

## CPC

- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00)
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61M 25/10185: {Valves}
- A61M 37/0015: {by using microneedles}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

## Claims

### Claim 1

(canceled)

### Claim 2

A therapeutic preparation comprising a exenatide, the preparation shaped as a solid tissue penetrating member having a pointed end, the preparation configured to be contained in a swallowable enclosure having a tubular shape with curved ends and to be released from the enclosure to penetrate and be inserted into a gastro-intestinal (GI) wall of a patient after oral ingestion of the enclosure by the application of force upon the preparation, wherein upon insertion into the GI wall, the preparation releases exenatide into the blood stream of the patient.

### Claim 3 (depends on 2)

The preparation of claim 2, wherein the preparation is adapted for insertion into a wall of the patient's small intestine.

### Claim 4 (depends on 2)

The preparation of claim 2, wherein the preparation is adapted for insertion into a wall of the patient's stomach.

### Claim 5 (depends on 2)

The preparation of claim 2, wherein the preparation is adapted to be operably coupled to a delivery means having a first configuration and a second configuration, the preparation being contained within the enclosure in the first configuration and advanced out of the capsule and into the GI wall in the second configuration.

### Claim 6 (depends on 5)

The preparation of claim 5, wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state.

### Claim 7 (depends on 5)

The preparation of claim 5, wherein the delivery means comprises a spring.

### Claim 8 (depends on 2)

The preparation of claim 2, wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release exenatide into the blood stream.

### Claim 9 (depends on 8)

The preparation of claim 8, wherein the biodegradable material comprises poly(lactic-co-glycolic acid) (PLGA), a sugar or maltose.

### Claim 10 (depends on 2)

The preparation of claim 2, wherein the preparation comprises at least one pharmaceutical excipient.

### Claim 11 (depends on 10)

The preparation of claim 10, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

### Claim 12 (depends on 11)

The preparation of claim 11, wherein the binder comprises polyethylene glycol (PEG).

### Claim 13 (depends on 2)

The preparation of claim 2, wherein a dose of exenatide in the preparation is in a range of about 1 to 20 μg.

### Claim 14 (depends on 1)

The preparation of claim 1 13, wherein a dose of exenatide in the preparation is in a range of about 1 to 10 μg.

### Claim 15 (depends on 1)

The preparation of claim 1 14, wherein a dose of exenatide in the preparation is in a range of about 4 to 8 μg.

### Claim 16 (depends on 2)

The preparation of claim 2, wherein a weight percent of exenatide in the tissue penetrating member comprises between about 0.1 to 1%.

### Claim 17 (depends on 2)

The preparation of claim 2, wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the GI wall after insertion.

### Claim 18 (depends on 2)

The preparation of claim 2, wherein the tissue penetrating member includes a shaped section in which the exenatide is contained.

### Claim 19 (depends on 18)

The preparation of claim 18, wherein the shaped section has a cylinder or pellet shape.

### Claim 20 (depends on 2)

The preparation of claim 2, wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.

### Claim 21 (depends on 2)

The preparation of claim 2, wherein the preparation is configured to produce a long-term release of exenatide.

### Claim 22 (depends on 21)

The preparation of claim 21, wherein the long term release of exanatide has a t½ in range of about 6 to 24 hours.

### Claim 23 (depends on 2)

The preparation of claim 2, wherein the preparation comprises a therapeutically effective dose of another therapeutic agent for the treatment of diabetes or another glucose regulation disorder.

### Claim 24 (depends on 23)

The preparation of claim 23, wherein the other therapeutic agent comprises a therapeutically effective dose of insulin.

### Claim 25 (depends on 24)

The preparation of claim 24, wherein a dose of insulin in the preparation is in a range from about 1 to 50 units of insulin or about 4 to 9 units of insulin.

### Claim 26 (depends on 23)

The preparation of claim 23, wherein the other therapeutic agent comprises metformin.

### Claim 27 (depends on 26)

The preparation of claim 26, wherein a dose of exenatide and a dose of metformin in the preparation are matched to control a blood glucose level of a patient without injecting incretin into the patient.

### Claim 28

A therapeutic preparation comprising a therapeutically effective dose exenatide for the control of a blood glucose level in a patient having diabetes or other blood glucose regulation disorder, the preparation shaped as a solid tissue penetrating member having a pointed end, the preparation configured to be contained in a swallowable enclosure having a tubular shape with curved ends and to be released from the enclosure to penetrate and be inserted into a gastro-intestinal (GI) wall of the patient after oral ingestion of the enclosure, wherein upon insertion into the GI wall, the preparation releases exenatide into the blood stream of the patient to control the blood glucose level in the patient.

### Claim 29 (depends on 28)

The preparation of claim 28, wherein the patient's blood glucose level is controlled within a normal physiologic range.

### Claim 30 (depends on 28)

The preparation of claim 28, wherein a dose of exenatide in the preparation is in a range of about 1 to 20 μg.
